L1CAM is expressed in triple-negative breast cancers and is inversely correlated with androgen receptor

Standard

L1CAM is expressed in triple-negative breast cancers and is inversely correlated with androgen receptor. / Doberstein, Kai; Milde-Langosch, Karin; Bretz, Niko P; Schirmer, Uwe; Harari, Ayelet; Witzel, Isabell; Ben-Arie, Alon; Hubalek, Michael; Müller-Holzner, Elisabeth; Reinold, Susanne; Zeimet, Alain G; Altevogt, Peter; Fogel, Mina.

In: BMC CANCER, Vol. 14, 15.12.2014, p. 958.

Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

Harvard

Doberstein, K, Milde-Langosch, K, Bretz, NP, Schirmer, U, Harari, A, Witzel, I, Ben-Arie, A, Hubalek, M, Müller-Holzner, E, Reinold, S, Zeimet, AG, Altevogt, P & Fogel, M 2014, 'L1CAM is expressed in triple-negative breast cancers and is inversely correlated with androgen receptor', BMC CANCER, vol. 14, pp. 958. https://doi.org/10.1186/1471-2407-14-958

APA

Doberstein, K., Milde-Langosch, K., Bretz, N. P., Schirmer, U., Harari, A., Witzel, I., Ben-Arie, A., Hubalek, M., Müller-Holzner, E., Reinold, S., Zeimet, A. G., Altevogt, P., & Fogel, M. (2014). L1CAM is expressed in triple-negative breast cancers and is inversely correlated with androgen receptor. BMC CANCER, 14, 958. https://doi.org/10.1186/1471-2407-14-958

Vancouver

Doberstein K, Milde-Langosch K, Bretz NP, Schirmer U, Harari A, Witzel I et al. L1CAM is expressed in triple-negative breast cancers and is inversely correlated with androgen receptor. BMC CANCER. 2014 Dec 15;14:958. https://doi.org/10.1186/1471-2407-14-958

Bibtex

@article{4e9f8d13e07a493581e41c490c91a845,
title = "L1CAM is expressed in triple-negative breast cancers and is inversely correlated with androgen receptor",
abstract = "BACKGROUND: Breast cancer is a heterogeneous disease displaying distinct molecular features and clinical outcome. The molecular profile of triple-negative breast cancers (TNBCs) overlaps with that of basal-like breast cancers that in turn show similarities with high-grade serous ovarian and endometrial carcinoma. L1CAM is an established biomarker for the latter cancers and we showed before that approximately 18% of primary breast cancers are positive for L1CAM and have a bad prognosis. Here we analysed the expression of L1CAM breast cancer subtypes.METHODS: We analyzed mRNA and protein expression data from different breast cancer cohorts for L1CAM, estrogen receptor, progesterone receptor, Her-2 and Androgen receptor (AR) and correlated the data. We performed Western blot analysis on tumor cell lysates and carried out chromatin-immuno-precipitation (CHIP) after AR overexpression.RESULTS: We find that L1CAM is expressed preferentially though not exclusively in TNBCs. Using the human cancer genome atlas database and two independent breast cancer cohorts we find that L1CAM is inversely correlated with androgen receptor (AR) expression. We found that L1CAM(high)AR(low) primary breast tumors have the worst clinical outcome. Overexpression of AR in MDA-MB436 breast cancer cells decreased L1CAM expression at the protein and mRNA level and CHIP-analysis revealed binding of AR to the L1CAM promoter region.CONCLUSIONS: These results suggest that L1CAM in breast cancer is under AR control. The data also strongly advocate the use of L1CAM assessment in breast cancer diagnosis. We suggest that L1CAM expression could be causally related to the bad prognosis of TNBCs.",
author = "Kai Doberstein and Karin Milde-Langosch and Bretz, {Niko P} and Uwe Schirmer and Ayelet Harari and Isabell Witzel and Alon Ben-Arie and Michael Hubalek and Elisabeth M{\"u}ller-Holzner and Susanne Reinold and Zeimet, {Alain G} and Peter Altevogt and Mina Fogel",
year = "2014",
month = dec,
day = "15",
doi = "10.1186/1471-2407-14-958",
language = "English",
volume = "14",
pages = "958",
journal = "BMC CANCER",
issn = "1471-2407",
publisher = "BioMed Central Ltd.",

}

RIS

TY - JOUR

T1 - L1CAM is expressed in triple-negative breast cancers and is inversely correlated with androgen receptor

AU - Doberstein, Kai

AU - Milde-Langosch, Karin

AU - Bretz, Niko P

AU - Schirmer, Uwe

AU - Harari, Ayelet

AU - Witzel, Isabell

AU - Ben-Arie, Alon

AU - Hubalek, Michael

AU - Müller-Holzner, Elisabeth

AU - Reinold, Susanne

AU - Zeimet, Alain G

AU - Altevogt, Peter

AU - Fogel, Mina

PY - 2014/12/15

Y1 - 2014/12/15

N2 - BACKGROUND: Breast cancer is a heterogeneous disease displaying distinct molecular features and clinical outcome. The molecular profile of triple-negative breast cancers (TNBCs) overlaps with that of basal-like breast cancers that in turn show similarities with high-grade serous ovarian and endometrial carcinoma. L1CAM is an established biomarker for the latter cancers and we showed before that approximately 18% of primary breast cancers are positive for L1CAM and have a bad prognosis. Here we analysed the expression of L1CAM breast cancer subtypes.METHODS: We analyzed mRNA and protein expression data from different breast cancer cohorts for L1CAM, estrogen receptor, progesterone receptor, Her-2 and Androgen receptor (AR) and correlated the data. We performed Western blot analysis on tumor cell lysates and carried out chromatin-immuno-precipitation (CHIP) after AR overexpression.RESULTS: We find that L1CAM is expressed preferentially though not exclusively in TNBCs. Using the human cancer genome atlas database and two independent breast cancer cohorts we find that L1CAM is inversely correlated with androgen receptor (AR) expression. We found that L1CAM(high)AR(low) primary breast tumors have the worst clinical outcome. Overexpression of AR in MDA-MB436 breast cancer cells decreased L1CAM expression at the protein and mRNA level and CHIP-analysis revealed binding of AR to the L1CAM promoter region.CONCLUSIONS: These results suggest that L1CAM in breast cancer is under AR control. The data also strongly advocate the use of L1CAM assessment in breast cancer diagnosis. We suggest that L1CAM expression could be causally related to the bad prognosis of TNBCs.

AB - BACKGROUND: Breast cancer is a heterogeneous disease displaying distinct molecular features and clinical outcome. The molecular profile of triple-negative breast cancers (TNBCs) overlaps with that of basal-like breast cancers that in turn show similarities with high-grade serous ovarian and endometrial carcinoma. L1CAM is an established biomarker for the latter cancers and we showed before that approximately 18% of primary breast cancers are positive for L1CAM and have a bad prognosis. Here we analysed the expression of L1CAM breast cancer subtypes.METHODS: We analyzed mRNA and protein expression data from different breast cancer cohorts for L1CAM, estrogen receptor, progesterone receptor, Her-2 and Androgen receptor (AR) and correlated the data. We performed Western blot analysis on tumor cell lysates and carried out chromatin-immuno-precipitation (CHIP) after AR overexpression.RESULTS: We find that L1CAM is expressed preferentially though not exclusively in TNBCs. Using the human cancer genome atlas database and two independent breast cancer cohorts we find that L1CAM is inversely correlated with androgen receptor (AR) expression. We found that L1CAM(high)AR(low) primary breast tumors have the worst clinical outcome. Overexpression of AR in MDA-MB436 breast cancer cells decreased L1CAM expression at the protein and mRNA level and CHIP-analysis revealed binding of AR to the L1CAM promoter region.CONCLUSIONS: These results suggest that L1CAM in breast cancer is under AR control. The data also strongly advocate the use of L1CAM assessment in breast cancer diagnosis. We suggest that L1CAM expression could be causally related to the bad prognosis of TNBCs.

U2 - 10.1186/1471-2407-14-958

DO - 10.1186/1471-2407-14-958

M3 - SCORING: Journal article

C2 - 25510351

VL - 14

SP - 958

JO - BMC CANCER

JF - BMC CANCER

SN - 1471-2407

ER -